Background: Patients with atopic dermatitis (AD) are prone to have skin infections. We aimed to investigate mRNA expression levels of various antimicrobial peptides and proteins (AMPs) in AD patients, and compare it with psoriasis vulgaris (PV) patients and healthy subjects. Methods: Skin biopsies were obtained from healthy subjects and patients with AD and PV. Quantitative real-time RT-PCR was used to determine the mRNA levels of human β-defensin (hBD)-1, hBD-2, hBD-3, LL-37, psoriasin, RNase 7, interferon-γ, and interleukin-10 (IL-10). Results: Except for LL-37, mRNA of hBDs, psoriasin, and RNase 7 was significantly higher expressed in AD (n = 42) and/or PV (n = 35) patients when compared to controls (n = 18). While PV lesions showed significantly higher mRNA hBD-2 levels than lesions of AD, the latter was associated with significantly higher mRNA levels of RNase 7 when compared to PV. A significant positive correlation of hBD expression was observed both in AD patients and PV patients. hBD mRNA levels of AD skin correlated with psoriasin and RNase 7 levels. hBD-1 mRNA expression correlated with AD activity and IL-10 mRNA expression. Conclusions: Most AMPs investigated in this study proved to be overexpressed in AD as well as PV when compared to controls. However, a statistically significant difference in AMP mRNA expression between AD and PV was only found for hBD-2 and RNase 7. A moderate-to-strong linear relationship between the mRNA expression of particular AMPs appears to exist in AD, and to a lesser extent in PV as well.

Keywords:
Antimicrobial peptides, Atopic dermatitis, Psoriasis vulgaris, Human β-defensin, Psoriasin, LL-37, RNase 7
1.
Izadpanath A, Gallo RL: Antimicrobial peptides. J Am Acad Dermatol 2005;52:381–390.
2.
Schroder JM, Harder J: Antimicrobial skin peptides and proteins. Cell Mol Life Sci 2006;63:469–486.
3.
Abramovits W: Atopic dermatitis. J Am Acad Dermatol. 2005;53(suppl 1):86–93.
4.
Krueger JG, Bowcock A: Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64(suppl 2):30–36.
5.
Biedermann T: Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 2006;86:99–109.
6.
Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982–986.
7.
Harder J, Schroder JM: Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 2005;77:476–486.
8.
Ong PY, Ohtake T, Brandt C, et al: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151–1160.
9.
Nomura I, Goleva E, Howell MD, et al: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262–3269.
10.
Kim JE, Kim BJ, Jeong MS, et al: Expression and modulation of LL-37 in normal human keratinocytes, HaCaT cells, and inflammatory skin diseases. J Korean Med Sci 2005;20:649–654.
11.
Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM: Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 2005;6:57–64.
12.
Harder J, Schroder JM: RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J Biol Chem 2002;277:46779–46784.
13.
Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92(suppl):44–47.
14.
Berth-Jones J: Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996;135:25–30.
15.
Giulietti A, Overbergh L, Valckx D, Decallone B, Bouillon R, Mathieu C: An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25:386–401.
16.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCT method. Methods 2001;25:402–408.
17.
Howell MD, Novak N, Bieber T, et al: Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005;125:738–745.
18.
de Jongh GJ, Zeeuwen PLJM, Kucharekova M, et al: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005;125:1163–1173.
19.
Gambichler T, Skrygan M, Tomi NS, Altmeyer P, Kreuter A: Changes of antimicrobial peptide mRNA expression in atopic eczema following phototherapy. Br J Dermatol 2006;155:1275–1278.
20.
Huh WK, Oono T, Shirafuji Y, et al: Dynamic alteration of human β-defensin 2 localization from cytoplasm to intercellular space in psoriatic skin. J Mol Med 2002;80:678–684.
21.
Hoover DM, Chertov O, Lubkowski J: The structure of human β-defensin-1: new insights into structural properties of β-defensins. J Biol Chem 2001;276:39021–39026.
22.
Howell MD, Boguniewicz M, Pastore S, et al: Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006;121:332–338.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.